• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pharming appoints Dr. Perry Calias chief scientific officer

Pharming appoints Dr. Perry Calias chief scientific officer

February 19, 2015
CenterWatch Staff

Pharming Group has appointed Dr. Perry Calias chief scientific officer. Calias will have overall responsibility for the company's new enzyme replacement therapy (ERT) programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.

Through the recent acquisition of TRM SASU, Pharming is expanding its validated platform for the production of recombinant human proteins. In order to take advantage of the available ERT development networks and expertise, Pharming also plans to open a small R&D office in Boston, Mass. Calias will be based in Boston and will split his time between there, Paris and Leiden.

Calias is a specialist in developing targeted therapies. As senior director for Shire within the Human Genetic Therapeutics division, he has championed the investigational effort for the intrathecal administration of recombinant enzymes for the treatment of the central nervous system (CNS) disorders associated with lysosomal storage diseases. In this capacity, he has led the research effort with regards to regulatory filings both within the U.S. and abroad, resulting in three clinical trials.

In addition, Calias has held various R&D positions at BBB Technologies, EyeGate Pharmaceuticals, Eyetech Pharmaceuticals, Draper Laboratories and Genzyme. Calias is listed as an inventor on over 30 domestic and foreign patents/applications spanning 18 different patent families, including mRNA therapeutics, new polyethylene glycol-linker chemistries, noninvasive ocular delivery devices, nucleic acid protecting strategies and combination anti-angiogenic therapies.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing